A compound or agent that combines with cyclooxygenases (EC 1.14.99.1) and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of icosanoids, prostaglandins, and thromboxanes.
| Member | Definition | Class |
|---|
| 2,3,6,8-tetrahydroxy-1-(3-methylbut-2-enyl)-5-(2-methylbut-3-en-2-yl)-9h-xanthen-9-one | A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 2, 3, 6 and 8, an isoprenyl group at position 1 and a 2-methylbut-3-en-2-yl group at position 5. It is isolated from the root barks of Cudrania tricuspidata and exhibits cytotoxicity towards human cancer cell lines. | cudratricusxanthone A |
| 6-methoxy-2-naphthylacetic acid | A monocarboxylic acid consisting of 2-naphthylacetic acid having a methoxy substituent at the 6-position. The active metabolite of the prodrug nabumetone. | (6-methoxy-2-naphthyl)acetic acid |
| aceclofenac | A monocarboxylic acid that is the carboxymethyl ester of diclofenac. A non-steroidal anti-inflammatory drug related to diclofenac, it is used in the management of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. | aceclofenac |
| acemetacin | A carboxylic ester that is the carboxymethyl ester of indometacin. A non-steroidal anti-inflammatory drug, it is used in the treatment of rheumatoid arthritis, osteoarthritis, and low back pain, as well as for postoperative pain and inflammation. Its activity is due to both acemetacin and its major metabolite, indometacin. | acemetacin |
| aiphanol | A lignan that is (2R)-2,3-dihydro-1,4-benzodioxin-2-ylmethanol which is substituted by a 2-(3,5-dihydroxyphenyl)ethenyl group at position 6 and a 4-hydroxy-3,5-dimethoxyphenyl group at position 3. It is a stilbenolignan isolated from the seeds of Aiphanes aculeata and exhibits potent inhibitory efficacy against cyclooxygenase-1 and -2 (COX-1 and COX-2). | aiphanol |
| ampiroxicam | A benzothiazine that is the 1-[(ethoxycarbonyl)oxy]ethyl ether of piroxicam. A prodrug for piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis. | ampiroxicam |
| ampyrone | A pyrazolone, a member of the class of pyrazoles that is antipyrine substituted at C-4 by an amino group. It is a metabolite of aminopyrine and of metamizole. | 4-aminoantipyrine |
| carprofen | Propanoic acid in which one of the methylene hydrogens is substituted by a 6-chloro-9H-carbazol-2-yl group. A non-steroidal anti-inflammatory drug, it is no longer used in human medicine but is still used for treatment of arthritis in elderly dogs. | carprofen |
| clonixin | A pyridinemonocarboxylic acid that is nicotinic acid substituted at position 2 by a (2-methyl-3-chlorophenyl)amino group. Used (as its lysine salt) for treatment of renal colic, muscular pain and moderately severe migraine attacks. | clonixin |
| diclofenac | A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position. | diclofenac |
| flufenamic acid | An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders. | flufenamic acid |
| flunixin | A pyridinemonocarboxylic acid that is nicotinic acid substituted at position 2 by a 2-methyl-3-(trifluoromethyl)phenylamino group. A relatively potent non-narcotic, nonsteroidal analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties; used in veterinary medicine (usually as the meglumine salt) for treatment of horses, cattle and pigs. | flunixin |
| flunixin meglumine | An organoammonium salt obtained by combining flunixin with one molar equivalent of 1-deoxy-1-(methylamino)-D-glucitol. A relatively potent non-narcotic, nonsteroidal analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties; used in veterinary medicine for treatment of horses, cattle and pigs. | flunixin meglumine |
| flurbiprofen | A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain. | flurbiprofen |
| ibufenac | A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 4-isobutylphenyl group. Although it was shown to be effective in treatment of rheumatoid arthritis, the clinical use of ibufenac was discontinued due to hepatotoxic side-effects. | ibufenac |
| indomethacin | A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis. | indometacin |
| indoprofen | A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(1-oxo-1,3-dihydroisoindol-2-yl)phenyl group. Initially used as an anti-inflammatory and analgesic, it was withdrawn from the market due to causing severe gastrointestinal bleeding. It has been subsequently found to increase production of the survival motor neuron protein. | indoprofen |
| ketoprofen | An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2. | ketoprofen |
| lonazolac | A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 3-(4-chlorophenyl)-1-phenylpyrazol-4-yl group. | lonazolac |
| loxoprofen | A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-[(2-oxocyclopentyl)methyl]phenyl group. A prodrug that is rapidly converted into its active trans-alcohol metabolite following oral administration. | loxoprofen |
| lysine clonixinate | An organoammonium salt obtained by combining clonixin with one molar equivalent of L-lysine. Used for treatment of renal colic, muscular pain and moderately severe migraine attacks. | clonixin lysine salt |
| meclofenamate sodium anhydrous | A hydrate that is the monohydrate of the sodium salt of meclofenamic acid. It is used for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis. | sodium meclofenamate monohydrate |
| meclofenamic acid | An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis. | meclofenamic acid |
| mefenamic acid | An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis. | mefenamic acid |
| mobiflex | A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries. | tenoxicam |
| naproxen-n-butyl nitrate | A carboxylic ester obtained by formal condensation of the carboxy group of naproxen with the hydroxy group of 4-(nitrooxy)butanol. A cyclooxygenase-inhibiting nitric oxide donator that is metabolised to naproxen and a nitric oxide donating moiety, effective in treatment of osteoarthritis. | naproxcinod |
| noramidopyrine | A member of the class of pyrazoles that is antipyrine substituted at C-4 by a methylamino group. It is a metabolite of aminopyrine and of metamizole. | 4-(methylamino)antipyrine |
| oxamethacin | A hydroxamic acid obtained by formal condensation of the carboxy group of indometacin with the amino group of hydroxylamine. | oxametacin |
| piroxicam | A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylic acid 1,1-dioxide with the exocyclic nitrogen of 2-aminopyridine. A non-steroidal anti-inflammatory drug of the oxicam class, it is used to relieve pain and works by preventing the production of endogenous prostaglandins involved in the mediation of pain, stiffness, tenderness and swelling. | piroxicam |
| proglumetacin | A carboxylic ester obtained by formal condensation of the carboxy group of indometacin with the hydroxy group of 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl N(2)-benzoyl-N,N-dipropyl-alpha-glutaminate. Used (as its dimaleate salt) to control pain and inflammation associated with musculoskeletal and joint disorders. Following oral administration, it is metabolised to indometacin and proglumide, a drug with antisecretory effects that helps prevent injury to the stomach lining. | proglumetacin |
| salicin | An aryl beta-D-glucoside that is salicyl alcohol in which the phenolic hydrogen has been replaced by a beta-D-glucosyl residue. | salicin |
| sulindac | A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions. | sulindac |
| suprofen | An aromatic ketone that is thiophene substituted at C-2 by a 4-(1-carboxyethyl)benzoyl group. | suprofen |
| tepoxalin | A hydroxamic acid obtained by formal condensation of the carboxy group of 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propanoic acid with the amino group of N-methylhydroxylamine. It is used in veterinary medicine for the control of pain and inflammation caused by musculoskeletal disorders such as hip dysplasia and arthritis in dogs. | tepoxalin |
| tofisopam | An organic sodium salt having loxoprofen(1-) as the counterion. The parent acid, loxoprofen, is a prodrug that is rapidly converted to its active trans-alcohol metabolite following oral administration. | loxoprofen sodium |
| tolfenamic acid | An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 3-chloro-2-methylphenyl group. Tolfenamic acid is used specifically for relieving the pain of migraine. It also shows anticancer activity. | tolfenamic acid |
| tolmetin | A monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug. | tolmetin |
| tolmetin sodium | An organic sodium salt that is the dihydrate form of tolmetin sodium. Used as a nonselective nonsteroidal anti-inflammatory drug. | tolmetin sodium dihydrate |
| tricin | The 3',5'-di-O-methyl ether of tricetin. Known commonly as tricin, it is a constituent of rice bran and has been found to potently inhibit colon cancer cell growth. | 3',5'-di-O-methyltricetin |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 23.4070 | 1 | 5 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 19.9526 | 1 | 1 |
| 67.9K protein | Vaccinia virus | Potency | 14.2807 | 2 | 5 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 43.6486 | 1 | 1 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 19.5376 | 2 | 8 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 24.0365 | 1 | 5 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 15.4618 | 1 | 2 |
| AR protein | Homo sapiens (human) | Potency | 19.2735 | 10 | 60 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 20.9492 | 2 | 13 |
| arylsulfatase A | Homo sapiens (human) | Potency | 8.8901 | 1 | 4 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 17.7578 | 2 | 6 |
| Ataxin-2 | Homo sapiens (human) | Potency | 1.9724 | 1 | 2 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 11.7969 | 1 | 4 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 1.9724 | 2 | 4 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 0.0045 | 2 | 4 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 66.7458 | 1 | 3 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 17.5724 | 1 | 3 |
| caspase-3 | Homo sapiens (human) | Potency | 17.5724 | 1 | 3 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 27.8304 | 2 | 13 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 10.0000 | 2 | 2 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 22.5821 | 1 | 9 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 8.5689 | 1 | 3 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 31.8234 | 1 | 3 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 33.9972 | 1 | 2 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 42.8000 | 1 | 2 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 8.7193 | 1 | 10 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 19.1012 | 1 | 8 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 0.2290 | 1 | 2 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 64.7760 | 2 | 11 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 8.7368 | 1 | 4 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 12.2506 | 1 | 12 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 16.8423 | 1 | 15 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 9.3822 | 1 | 3 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 20.4839 | 1 | 2 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 16.0977 | 2 | 20 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 12.6688 | 1 | 7 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 34.4564 | 1 | 7 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 10.6376 | 1 | 6 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 69.4850 | 1 | 3 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 7.5193 | 1 | 1 |
| endonuclease IV | Escherichia coli | Potency | 17.7828 | 1 | 1 |
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1 | 1 |
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1 | 1 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 17.4650 | 12 | 72 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 18.9103 | 2 | 16 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 39.4387 | 6 | 29 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 18.2447 | 1 | 13 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 21.3869 | 4 | 16 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 21.5657 | 4 | 10 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 5.9728 | 1 | 1 |
| G | Vesicular stomatitis virus | Potency | 16.8423 | 1 | 15 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 16.0977 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 16.0977 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 16.0977 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 16.0977 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 16.0977 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 16.0977 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 16.0977 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 16.0977 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 16.0977 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 16.0977 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 16.0977 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 16.0977 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 16.0977 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 16.0977 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 16.0977 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 16.0977 | 1 | 10 |
| geminin | Homo sapiens (human) | Potency | 11.6249 | 2 | 19 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 17.7769 | 2 | 12 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 20.8954 | 2 | 2 |
| GLS protein | Homo sapiens (human) | Potency | 23.2739 | 2 | 9 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 11.0576 | 1 | 3 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 15.3246 | 4 | 19 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 15.6906 | 1 | 4 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 13.5546 | 1 | 2 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 16.5311 | 1 | 2 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 28.1152 | 1 | 4 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 25.5776 | 1 | 6 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 13.2702 | 2 | 38 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 26.3882 | 1 | 6 |
| histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 33.0412 | 2 | 12 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 74.4657 | 2 | 3 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 41.4904 | 1 | 2 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 16.8423 | 1 | 15 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 6.6943 | 2 | 3 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 21.9375 | 2 | 8 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 7.6401 | 2 | 22 |
| IDH1 | Homo sapiens (human) | Potency | 15.3644 | 1 | 2 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 13.5546 | 1 | 2 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 16.8423 | 1 | 30 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1 | 1 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 10.0000 | 1 | 1 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 10.0000 | 1 | 1 |
| Interferon beta | Homo sapiens (human) | Potency | 20.2062 | 2 | 18 |
| interleukin 8 | Homo sapiens (human) | Potency | 66.8242 | 1 | 1 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 3.7420 | 1 | 10 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 29.0254 | 3 | 31 |
| luciferase | Photuris pensylvanica (Pennsylania firefly) | Potency | 14.1254 | 1 | 1 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 0.5889 | 2 | 4 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 0.7943 | 1 | 1 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 25.7838 | 1 | 6 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 4.4761 | 2 | 2 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 1 | 1 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 27.1424 | 1 | 5 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 0.5889 | 1 | 2 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 0.5889 | 1 | 2 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 8.7169 | 1 | 2 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 0.0100 | 2 | 2 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 4.4476 | 1 | 4 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 0.0891 | 1 | 1 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 38.3975 | 3 | 17 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 32.6427 | 1 | 1 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 30.5577 | 1 | 8 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 9.4392 | 1 | 1 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 20.3381 | 2 | 12 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 0.1000 | 1 | 1 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 33.2618 | 3 | 18 |
| P53 | Homo sapiens (human) | Potency | 10.0000 | 1 | 1 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 23.1193 | 1 | 3 |
| Parkin | Homo sapiens (human) | Potency | 13.9520 | 1 | 2 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 15.8275 | 2 | 6 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 64.5923 | 1 | 3 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 17.6875 | 5 | 32 |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | Potency | 31.8326 | 1 | 2 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 18.4906 | 5 | 20 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 50.0685 | 2 | 8 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 4.4668 | 1 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 11.0344 | 1 | 2 |
| PPM1D protein | Homo sapiens (human) | Potency | 37.0259 | 1 | 2 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 31.8724 | 2 | 10 |
| progesterone receptor | Homo sapiens (human) | Potency | 24.1577 | 2 | 14 |
| pyruvate kinase | Leishmania mexicana mexicana | Potency | 15.8489 | 2 | 2 |
| pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 39.8107 | 2 | 3 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 50.1187 | 1 | 1 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 28.5482 | 2 | 23 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 3.3129 | 1 | 2 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 19.2984 | 1 | 2 |
| relaxin receptor 1 isoform 1 | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 30.1486 | 3 | 18 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 17.8870 | 4 | 25 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 4.6451 | 1 | 1 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 28.3072 | 1 | 2 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 19.2201 | 2 | 24 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 19.2201 | 2 | 24 |
| snurportin-1 | Homo sapiens (human) | Potency | 13.5546 | 1 | 2 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 16.1024 | 1 | 7 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 10.7750 | 1 | 4 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 18.1876 | 1 | 7 |
| TDP1 protein | Homo sapiens (human) | Potency | 19.1109 | 2 | 29 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 69.6219 | 1 | 2 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 33.1308 | 4 | 8 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 25.1261 | 3 | 21 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 31.3540 | 1 | 2 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 13.8000 | 4 | 6 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 10.6376 | 1 | 6 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 4.4668 | 1 | 1 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 4.4668 | 1 | 1 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 55.5278 | 1 | 2 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 23.6799 | 2 | 6 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 15.8461 | 5 | 24 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 42.8067 | 1 | 9 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 15.6906 | 1 | 4 |
| Vpr | Human immunodeficiency virus 1 | Potency | 12.5893 | 1 | 1 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 3',5'-cyclic-AMP phosphodiesterase | Sus scrofa (pig) | IC50 | 1,000.0000 | 1 | 1 |
| Acid-sensing ion channel 1 | Rattus norvegicus (Norway rat) | IC50 | 596.5570 | 1 | 2 |
| Acid-sensing ion channel 3 | Rattus norvegicus (Norway rat) | IC50 | 322.9780 | 1 | 2 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | IC50 | 164.0000 | 1 | 1 |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | IC50 | 164.0000 | 1 | 1 |
| Albumin | Homo sapiens (human) | Ki | 221,583,216,666.6666 | 1 | 6 |
| Aldo-keto reductase family 1 member B1 | Bos taurus (cattle) | IC50 | 3.4310 | 2 | 3 |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | IC50 | 72.3843 | 3 | 7 |
| Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | IC50 | 17.2850 | 4 | 6 |
| Aldo-keto reductase family 1 member C1 | Homo sapiens (human) | IC50 | 44.2250 | 5 | 10 |
| Aldo-keto reductase family 1 member C1 | Homo sapiens (human) | Ki | 0.8100 | 1 | 1 |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | IC50 | 22.1606 | 11 | 16 |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | Ki | 0.2200 | 1 | 1 |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | IC50 | 1.9467 | 15 | 20 |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | Ki | 0.9863 | 4 | 6 |
| Aldo-keto reductase family 1 member C4 | Homo sapiens (human) | IC50 | 94.2500 | 3 | 8 |
| Amyloid-beta precursor protein | Homo sapiens (human) | IC50 | 305.0000 | 1 | 1 |
| Androgen receptor | Homo sapiens (human) | IC50 | 51.6333 | 3 | 3 |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 | 123.4286 | 1 | 7 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | IC50 | 30.0000 | 1 | 2 |
| Beta-lactamase | Escherichia coli K-12 | IC50 | 350.0000 | 1 | 1 |
| Bifunctional epoxide hydrolase 2 | Homo sapiens (human) | IC50 | 1.0000 | 1 | 1 |
| Bile salt export pump | Homo sapiens (human) | IC50 | 177.9432 | 5 | 19 |
| Bile salt export pump | Rattus norvegicus (Norway rat) | IC50 | 87.5000 | 1 | 1 |
| C-X-C chemokine receptor type 1 | Homo sapiens (human) | IC50 | 5.0060 | 2 | 2 |
| C-X-C chemokine receptor type 3 | Homo sapiens (human) | IC50 | 0.0500 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase type II subunit alpha | Rattus norvegicus (Norway rat) | Ki | 5.1000 | 1 | 1 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 | 153.4000 | 2 | 5 |
| Carbonic anhydrase 1 | Homo sapiens (human) | IC50 | 666.6250 | 3 | 8 |
| Carbonic anhydrase 2 | Homo sapiens (human) | IC50 | 666.6250 | 3 | 8 |
| Carbonic anhydrase 4 | Bos taurus (cattle) | IC50 | 100.0000 | 2 | 4 |
| Carbonic anhydrase 9 | Homo sapiens (human) | IC50 | 100.0000 | 2 | 2 |
| Caspase-1 | Homo sapiens (human) | IC50 | 15.2460 | 1 | 10 |
| Caspase-3 | Homo sapiens (human) | IC50 | 15.2460 | 1 | 10 |
| Caspase-4 | Homo sapiens (human) | IC50 | 15.2460 | 1 | 10 |
| Caspase-5 | Homo sapiens (human) | IC50 | 15.2460 | 1 | 10 |
| Caspase-9 | Homo sapiens (human) | IC50 | 15.2460 | 1 | 10 |
| Chain A, membrane-associated prostaglandin E synthase-2 | Macaca fascicularis (crab-eating macaque) | IC50 | 1,000.0000 | 1 | 1 |
| cysteine protease ATG4B isoform a | Homo sapiens (human) | IC50 | 8.1700 | 1 | 1 |
| Cytochrome c oxidase subunit 2 | Homo sapiens (human) | IC50 | 18.8850 | 4 | 6 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 5 |
| Cytochrome P450 2C9 | Homo sapiens (human) | Ki | 163,388,500,012.1750 | 3 | 4 |
| Cytochrome P450 2J2 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 5 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| Cytochrome P450 3A4 | Homo sapiens (human) | Ki | 1,640.0000 | 1 | 3 |
| Cytosolic phospholipase A2 gamma | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Dehydrogenase/reductase SDR family member 9 | Homo sapiens (human) | IC50 | 14.0000 | 1 | 1 |
| Dihydrofolate reductase | Homo sapiens (human) | Ki | 116.0000 | 1 | 2 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Homo sapiens (human) | IC50 | 10.5000 | 1 | 2 |
| Epidermal growth factor receptor | Homo sapiens (human) | IC50 | 10.0000 | 1 | 3 |
| Fatty acid-binding protein, intestinal | Homo sapiens (human) | Ki | 33.9500 | 2 | 8 |
| Fatty acid-binding protein, liver | Rattus norvegicus (Norway rat) | Ki | 53.0881 | 2 | 8 |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | IC50 | 27.1500 | 2 | 2 |
| Indoleamine 2,3-dioxygenase 1 | Mus musculus (house mouse) | IC50 | 0.0820 | 1 | 2 |
| Interleukin-8 | Homo sapiens (human) | IC50 | 0.2870 | 1 | 4 |
| Lactoylglutathione lyase | Homo sapiens (human) | Ki | 279.6154 | 3 | 13 |
| Malate dehydrogenase, cytoplasmic | Homo sapiens (human) | IC50 | 225.0000 | 1 | 1 |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | IC50 | 4.5355 | 1 | 2 |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | IC50 | 500.0000 | 1 | 2 |
| Multidrug resistance-associated protein 1 | Homo sapiens (human) | IC50 | 12.3000 | 2 | 2 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 | 96.2571 | 1 | 7 |
| Myc proto-oncogene protein | Homo sapiens (human) | IC50 | 403.0000 | 1 | 1 |
| Myeloperoxidase | Homo sapiens (human) | IC50 | 1.5950 | 2 | 2 |
| NACHT, LRR and PYD domains-containing protein 3 | Mus musculus (house mouse) | IC50 | 25.0000 | 1 | 1 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | IC50 | 0.0040 | 1 | 1 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | IC50 | 0.0040 | 1 | 1 |
| Nicotinate phosphoribosyltransferase | Homo sapiens (human) | Ki | 0.0001 | 1 | 3 |
| Nitric oxide synthase, inducible | Mus musculus (house mouse) | IC50 | 24.3500 | 5 | 5 |
| P2Y purinoceptor 12 | Rattus norvegicus (Norway rat) | IC50 | 0.4900 | 1 | 2 |
| phospholipase A2 precursor | Homo sapiens (human) | IC50 | 7.7400 | 1 | 1 |
| Phospholipase A2, major isoenzyme | Sus scrofa (pig) | IC50 | 1,000.0000 | 1 | 1 |
| Polyunsaturated fatty acid 5-lipoxygenase | Rattus norvegicus (Norway rat) | IC50 | 316.5000 | 11 | 13 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 | 301.9950 | 1 | 1 |
| Procathepsin L | Homo sapiens (human) | IC50 | 11.8000 | 1 | 1 |
| Prostaglandin D2 receptor | Mus musculus (house mouse) | IC50 | 10.0000 | 1 | 1 |
| Prostaglandin D2 receptor | Mus musculus (house mouse) | Ki | 10.0000 | 2 | 2 |
| Prostaglandin D2 receptor 2 | Homo sapiens (human) | Ki | 4.0250 | 2 | 2 |
| Prostaglandin E synthase | Homo sapiens (human) | IC50 | 60.3000 | 2 | 2 |
| Prostaglandin E2 receptor EP1 subtype | Mus musculus (house mouse) | Ki | 10.0000 | 2 | 2 |
| Prostaglandin E2 receptor EP2 subtype | Mus musculus (house mouse) | Ki | 10.0000 | 2 | 2 |
| Prostaglandin E2 receptor EP3 subtype | Mus musculus (house mouse) | Ki | 10.0000 | 2 | 2 |
| Prostaglandin E2 receptor EP4 subtype | Mus musculus (house mouse) | Ki | 10.0000 | 2 | 2 |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | IC50 | 6.2842 | 72 | 96 |
| Prostaglandin G/H synthase 1 | Mus musculus (house mouse) | IC50 | 0.0110 | 2 | 2 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | IC50 | 2.6497 | 89 | 129 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | Ki | 4.4500 | 2 | 2 |
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | IC50 | 18.0585 | 13 | 17 |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | IC50 | 0.8629 | 13 | 15 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | IC50 | 9.4709 | 120 | 164 |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | IC50 | 1.0374 | 21 | 35 |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | IC50 | 63.1725 | 29 | 33 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | Ki | 1.5000 | 1 | 1 |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | Ki | 9.8600 | 1 | 1 |
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | IC50 | 12.4535 | 7 | 11 |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | IC50 | 0.9145 | 12 | 14 |
| Prostaglandin-H2 D-isomerase | Mus musculus (house mouse) | IC50 | 1.1000 | 2 | 2 |
| Pyruvate kinase PKM | Homo sapiens (human) | IC50 | 21.0000 | 1 | 1 |
| Retinoic acid receptor RXR-alpha | Homo sapiens (human) | IC50 | 82.9000 | 1 | 1 |
| Rho-associated protein kinase 2 | Rattus norvegicus (Norway rat) | IC50 | 7.7000 | 1 | 2 |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | IC50 | 130.0000 | 1 | 1 |
| Serum paraoxonase/arylesterase 1 | Homo sapiens (human) | Ki | 4,471.0000 | 1 | 3 |
| Sialidase | Clostridium perfringens | IC50 | 0.2450 | 1 | 1 |
| Sialidase | Clostridium perfringens | Ki | 0.1748 | 2 | 2 |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | IC50 | 0.4900 | 1 | 1 |
| Sodium- and chloride-dependent betaine transporter | Rattus norvegicus (Norway rat) | IC50 | 0.3500 | 1 | 2 |
| Sodium- and chloride-dependent GABA transporter 1 | Rattus norvegicus (Norway rat) | IC50 | 0.3500 | 1 | 2 |
| Sodium- and chloride-dependent GABA transporter 2 | Rattus norvegicus (Norway rat) | IC50 | 0.3500 | 1 | 2 |
| Sodium- and chloride-dependent GABA transporter 3 | Rattus norvegicus (Norway rat) | IC50 | 0.3500 | 1 | 2 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | IC50 | 14.0000 | 1 | 1 |
| Solute carrier family 22 member 11 | Homo sapiens (human) | Ki | 107.8000 | 1 | 1 |
| Solute carrier family 22 member 6 | Homo sapiens (human) | IC50 | 5.2833 | 2 | 6 |
| Solute carrier family 22 member 6 | Rattus norvegicus (Norway rat) | IC50 | 0.5000 | 1 | 1 |
| Solute carrier family 22 member 6 | Homo sapiens (human) | Ki | 19.8000 | 1 | 1 |
| Solute carrier family 22 member 6 | Rattus norvegicus (Norway rat) | Ki | 22.0667 | 2 | 3 |
| Solute carrier family 22 member 7 | Rattus norvegicus (Norway rat) | Ki | 1.8400 | 1 | 1 |
| Solute carrier family 22 member 8 | Homo sapiens (human) | Ki | 592.7075 | 2 | 4 |
| Solute carrier organic anion transporter family member 1A3 | Rattus norvegicus (Norway rat) | Ki | 1,450.0000 | 1 | 2 |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | IC50 | 12.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | Ki | 11.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | IC50 | 41.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | Ki | 38.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | IC50 | 140.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | Ki | 130.0000 | 1 | 1 |
| Substance-P receptor | Cavia porcellus (domestic guinea pig) | IC50 | 5.7000 | 1 | 1 |
| Thromboxane-A synthase | Homo sapiens (human) | IC50 | 50.0500 | 2 | 2 |
| Transcription factor SOX-18 | Mus musculus (house mouse) | IC50 | 191.5000 | 2 | 4 |
| Transcriptional enhancer factor TEF-3 | Homo sapiens (human) | IC50 | 54.0000 | 1 | 1 |
| Transient receptor potential cation channel subfamily M member 2 | Homo sapiens (human) | IC50 | 88.0000 | 2 | 3 |
| Transthyretin | Homo sapiens (human) | IC50 | 2.9000 | 1 | 1 |
| UDP-glucuronosyltransferase 1-6 | Homo sapiens (human) | IC50 | 131.0000 | 1 | 3 |
| UDP-glucuronosyltransferase 1-6 | Homo sapiens (human) | Ki | 23.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | IC50 | 131.0000 | 1 | 3 |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | Ki | 52.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A10 | Homo sapiens (human) | Ki | 28.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A4 | Homo sapiens (human) | IC50 | 131.0000 | 1 | 3 |
| UDP-glucuronosyltransferase 1A7 | Homo sapiens (human) | Ki | 19.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A9 | Homo sapiens (human) | Ki | 11.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 2B10 | Homo sapiens (human) | IC50 | 131.0000 | 1 | 3 |
| UDP-glucuronosyltransferase 2B7 | Homo sapiens (human) | IC50 | 131.0000 | 1 | 3 |
| Uracil nucleotide/cysteinyl leukotriene receptor | Homo sapiens (human) | IC50 | 28.8000 | 2 | 2 |